CN107669760A - A kind of blood-fat reducing composition and application thereof and compound preparation - Google Patents

A kind of blood-fat reducing composition and application thereof and compound preparation Download PDF

Info

Publication number
CN107669760A
CN107669760A CN201710783652.0A CN201710783652A CN107669760A CN 107669760 A CN107669760 A CN 107669760A CN 201710783652 A CN201710783652 A CN 201710783652A CN 107669760 A CN107669760 A CN 107669760A
Authority
CN
China
Prior art keywords
blood
parts
reducing composition
fat reducing
jasmine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710783652.0A
Other languages
Chinese (zh)
Inventor
张红雨
刘成
孙光辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhengzhou Haisiwei Biological Technology Co Ltd
Original Assignee
Zhengzhou Haisiwei Biological Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhengzhou Haisiwei Biological Technology Co Ltd filed Critical Zhengzhou Haisiwei Biological Technology Co Ltd
Priority to CN201710783652.0A priority Critical patent/CN107669760A/en
Publication of CN107669760A publication Critical patent/CN107669760A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to medical supplies technical field, and in particular to a kind of blood-fat reducing composition and application thereof and compound preparation, the blood-fat reducing composition include jasmine extractive from fermentative, haw thorn extract and kudzu root extract.In the present invention, Jasmine, hawthorn and the root of kudzu vine have many pharmacological effects in itself, contain a variety of human endogenous's property materials, small active peptides, amino acid, trace element, flavones, polysaccharide, unrighted acid etc. the material beneficial to human body in compound preparation, it is that the blood-fat reducing composition of the present invention has reducing blood lipid, hypotensive, reduces atheroma, improves immunity etc. effect, raw materials of the present invention come from integration of drinking and medicinal herbs, without any toxic side effect.

Description

A kind of blood-fat reducing composition and application thereof and compound preparation
Technical field
The present invention relates to medical supplies technical field, and in particular to a kind of blood-fat reducing composition and application thereof and compound system Agent.
Background technology
Hyperlipidemia refers to that blood lipid level is too high, the disease that can directly cause some to seriously endanger health, such as artery Atherosis, coronary heart disease, pancreatitis etc..Blood fat is the general name of contained lipoids in blood.Mainly comprising cholesterol, sweet in blood fat Oily three fat (i.e. neutral fat), phosphatide, aliphatic acid etc..Blood fat, which increases, is high fat of blood, but is commonly referred to as hyperlipemia in clinical high fat of blood Disease.Hyperlipidemia is a kind of common disease, and the incidence of disease is high among the elderly, and it causes atherosclerosis, or even coronary disease Disease, cerebral thrombus, cerebral hemorrhage etc., threat to life.Therefore, hyperlipidemia is not only blood fat height a bit, and its seriousness can not definitely neglect Depending on.The reason for Hyperlipemia is that the fatty and cholesterol food of feed is excessive, while has relation with inherent cause etc..
Infringement of the high fat of blood to body be concealment, gradually, progressive and systemic, its direct infringement is to accelerate whole body Atherosclerosis, because the vitals of whole body will rely on artery blood supply, oxygen supply, once artery is blocked by atheromatous plaque, It may result in serious consequence.Renal failure caused by artery sclerosis etc., it is all closely related with hyperlipemia.Numerous studies data Show, hyperlipemia is cerebral apoplexy, coronary heart disease, myocardial infarction, cardiac sudden death independently important hazards.
Hyperlipemia refers to that the concentration of the lipid compositions such as plasma cholesterol, triglycerides, total fat exceedes arm's length standard.High blood The main harm of fat disease is to cause atherosclerosis, and then causes numerous relevant diseases, and most common of which one kind is fatal Property disease is exactly coronary heart disease, and serious hyperlipemia can cause acute pancreatitis, be another fatal disease.
In addition, hyperlipemia is also to promote hypertension, IGT, an important risk factor of diabetes.High blood Fat disease can also result in fatty liver, hepatic sclerosis, cholelithiasis, pancreatitis, fundus hemorrhage, blindness, peripheral vascular disease, limping, high urine Acidaemia.Some primary and familial hyperlipemia it may also occur that tendon shape, nodositas, the palm plane and eye socket around yellow Knurl, embryotoxon etc..
As China human mortality aging trend is accelerated, living standard gradually steps up, the increasing direct prestige of the three high patients Our health is coerced, a large amount of medical researches show that the treatment method of high fat of blood can not will also be stayed only by drug-layer side The maintenance of meaning body, Reducing Blood Lipid by Chinese medicine preparation that is effective, having no toxic side effect is developed, will be the increasing high fat of blood in China People brings glad tidings, while reduces patient because high fat of blood, hypertension produce the possibility of various complication, and patient's warp is greatly reduced Ji burden, save the valuable medical resource in China.
The content of the invention
In order to overcome shortcoming and defect present in prior art, it is an object of the invention to provide one kind to have drop blood Fat, hypotensive, reduce atheroma, the blood-fat reducing composition for improving immunity etc. effect and application thereof and compound preparation.
The purpose of the present invention is achieved through the following technical solutions：
A kind of blood-fat reducing composition, include the raw material of following parts by weight：
Jasmine extractive from fermentative 10-80 parts
Haw thorn extract 5-20 parts
Kudzu root extract 5-20 parts.
Preferably, the blood-fat reducing composition includes the raw material of following parts by weight：
Jasmine extractive from fermentative 20-70 parts
Haw thorn extract 10-15 parts
Kudzu root extract 10-15 parts.
Preferably, the blood-fat reducing composition includes the raw material of following parts by weight：
Jasmine extractive from fermentative 30-60 parts
Haw thorn extract 10-15 parts
Kudzu root extract 10-15 parts.
Preferably, the blood-fat reducing composition includes the raw material of following parts by weight：
45 parts of jasmine extractive from fermentative
12.5 parts of haw thorn extract
12.5 parts of kudzu root extract.
The mechanism of each raw material of the blood-fat reducing composition of the present invention is as follows：
Jasmine extractive from fermentative：Property it is sweet, temperature, have qi-regulating, open it is strongly fragrant, ward off it is dirty and in and other effects.
Haw thorn extract：It is sour, sweet, tepor, returns spleen, stomach, Liver Channel, contain crataegolic acid, citric acid, lipolysis acid, dimension The compositions such as raw plain C, flavones, carbohydrate, have expansion blood vessel, improve microcirculation, reduce blood pressure, promote Cholesterol Excretion and Reduce the effect such as blood fat.
Kudzu root extract：It is sweet, pungent, it is cool, there is expelling pathogenic factors from muscles and skin to bring down a fever, promoting eruption, promote the production of body fluid to quench thirst, the work(of Shengyang Zhixie, in the present invention, Its abundant flavone compound can reduce serum cholesterol, oily three esters be reduced, so as to improve the reducing blood lipid of the present composition Effect.
The present invention by each Chinese medicine carry out reasonable compatibility reach reducing blood lipid, hypotensive, reduce atheroma, improve exempt from Epidemic disease power etc. acts on, and raw materials come from integration of drinking and medicinal herbs, without any toxic side effect.
Wherein, the preparation method of the jasmine extractive from fermentative is：Jasmine powder and antarctic candidia lipase are added Fermented into solvent orange 2 A, it be 7-8 to control fermentation pH, and fermentation temperature is 40-70 DEG C, filtered, concentrate, be overcritical after fermentation Extraction obtains the jasmine extractive from fermentative.
Preferably, the weight ratio of the jasmine powder and antarctic candidia lipase is 15-25:1, the solvent orange 2 A can be with For the mixed liquor or absolute ethyl alcohol of water, water and ethanol arbitrary proportion, preferably absolute ethyl alcohol.
Wherein, the preparation method of the haw thorn extract is：5-15Kg hawthorn is taken to add to 15-25L volume fraction For in 40%-60% ethanol, after being well mixed and soaking 1-3h, high-pressure homogeneous processing 1- is carried out with 200-400MPa pressure 5min, then decompression filter, obtain filtrate, filtrate is evaporated to the haw thorn extract for obtaining general flavone content 80%-85%.
Wherein, the hawthorn is Shanxi Wild hawthorn.
Wherein, the extracting method of the kudzu root extract is：Kudzu-vine root powder is subjected to heating and refluxing extraction 2 times, filtering, merged Filtrate, concentration obtain the kudzu root extract, wherein the solvent that uses of each heating and refluxing extraction is 70%- for volume parts 90% ethanol solution.
Wherein, the hawthorn is Shanxi Wild hawthorn.
Wherein, the root of kudzu vine is Jiuhuashan Wild Pueraria.
Present invention also offers a kind of purposes of blood-fat reducing composition as described above：The blood-fat reducing composition is used for Pharmaceuticals field.
Present invention also offers a kind of compound preparation for reducing blood fat：Will a kind of blood-fat reducing composition as described above with it is medicinal auxiliary Expect compound preparation made of mixed pressuring plate.The pharmaceutic adjuvant be pharmaceutically acceptable carrier, excipient, diluent it is a kind of or Two or more combinations, its usage ratio can be obtained by the traditional regulation of prior art.
The beneficial effects of the present invention are：In the present invention, Jasmine, hawthorn and the root of kudzu vine have many pharmacological effects in itself, Contain a variety of human endogenous's property materials, small active peptides, amino acid, trace element, flavones, polysaccharide, insatiable hunger in compound preparation The material beneficial to human body with aliphatic acid etc., it is that the blood-fat reducing composition of the present invention has reducing blood lipid, hypotensive, reduces artery Gruel type, immunity etc. effect is improved, raw materials of the present invention come from integration of drinking and medicinal herbs, without any toxic side effect.
Embodiment
For the ease of the understanding of those skilled in the art, with reference to embodiment, the present invention is further illustrated, real The content that the mode of applying refers to not is limitation of the invention.
Embodiment 1
A kind of blood-fat reducing composition, include the raw material of following parts by weight：
45 parts of jasmine extractive from fermentative
12.5 parts of haw thorn extract
12.5 parts of kudzu root extract.
Wherein, the preparation method of the jasmine extractive from fermentative is：Jasmine powder and antarctic candidia lipase are added Fermented into solvent orange 2 A, it is 7.5 to control fermentation pH, and fermentation temperature is 55 DEG C, after fermentation, filtered, concentration, overcritical extraction Take and obtain the jasmine extractive from fermentative.
Preferably, the weight ratio of the jasmine powder and antarctic candidia lipase is 20:1, the solvent orange 2 A is anhydrous second Alcohol.
Wherein, the preparation method of the haw thorn extract is：Take 10Kg hawthorn add to 20L volume fraction be 50% Ethanol in, it is well mixed and after soaking 2h, high-pressure homogeneous processing 3min is carried out with 300MPa pressure, then decompression filters, and obtains To filtrate, filtrate is evaporated to the haw thorn extract for obtaining general flavone content 83.7%.
Wherein, the extracting method of the kudzu root extract is：Kudzu-vine root powder is subjected to heating and refluxing extraction 2 times, filtering, merged Filtrate, concentration obtain the kudzu root extract, wherein the solvent that uses of each heating and refluxing extraction is 80% for volume parts Ethanol solution.
Wherein, the hawthorn is Shanxi Wild hawthorn.
Wherein, the root of kudzu vine is Jiuhuashan Wild Pueraria.
Embodiment 2
A kind of blood-fat reducing composition, include the raw material of following parts by weight：
10 parts of jasmine extractive from fermentative
5 parts of haw thorn extract
5 parts of kudzu root extract.
Wherein, the preparation method of the jasmine extractive from fermentative is：Jasmine powder and antarctic candidia lipase are added Fermented into solvent orange 2 A, it is 7 to control fermentation pH, and fermentation temperature is 40 DEG C, after fermentation, filtered, concentration, supercritical extract Obtain the jasmine extractive from fermentative.
Preferably, the weight ratio of the jasmine powder and antarctic candidia lipase is 15:1, the solvent orange 2 A is anhydrous second Alcohol.
Wherein, the preparation method of the haw thorn extract is：Take 5Kg hawthorn add to 15L volume fraction be 40% Ethanol in, it is well mixed and after soaking 1h, high-pressure homogeneous processing 1min is carried out with 200MPa pressure, then decompression filters, and obtains To filtrate, filtrate is evaporated to the haw thorn extract for obtaining general flavone content 80%.
Wherein, the extracting method of the kudzu root extract is：Kudzu-vine root powder is subjected to heating and refluxing extraction 2 times, filtering, merged Filtrate, concentration obtain the kudzu root extract, wherein the solvent that uses of each heating and refluxing extraction is 70% for volume parts Ethanol solution.
Wherein, the hawthorn is Shanxi Wild hawthorn.
Wherein, the root of kudzu vine is Jiuhuashan Wild Pueraria.
Embodiment 3
A kind of blood-fat reducing composition, include the raw material of following parts by weight：
80 parts of jasmine extractive from fermentative
20 parts of haw thorn extract
20 parts of kudzu root extract.
Wherein, the preparation method of the jasmine extractive from fermentative is：Jasmine powder and antarctic candidia lipase are added Fermented into solvent orange 2 A, it is 8 to control fermentation pH, and fermentation temperature is 70 DEG C, after fermentation, filtered, concentration, supercritical extract Obtain the jasmine extractive from fermentative.
Preferably, the weight ratio of the jasmine powder and antarctic candidia lipase is 25:1, the solvent orange 2 A is anhydrous second Alcohol.
Wherein, the preparation method of the haw thorn extract is：Take 15Kg hawthorn add to 25L volume fraction be 60% Ethanol in, it is well mixed and after soaking 3h, high-pressure homogeneous processing 5min is carried out with 400MPa pressure, then decompression filters, and obtains To filtrate, filtrate is evaporated to the haw thorn extract for obtaining general flavone content 85%.
Wherein, the extracting method of the kudzu root extract is：Kudzu-vine root powder is subjected to heating and refluxing extraction 2 times, filtering, merged Filtrate, concentration obtain the kudzu root extract, wherein the solvent that uses of each heating and refluxing extraction is 90% for volume parts Ethanol solution.
Wherein, the hawthorn is Shanxi Wild hawthorn.
Wherein, the root of kudzu vine is Jiuhuashan Wild Pueraria.
Embodiment 4
A kind of blood-fat reducing composition, include the raw material of following parts by weight：
60 parts of jasmine extractive from fermentative
12 parts of haw thorn extract
17 parts of kudzu root extract.
Wherein, the preparation method of the jasmine extractive from fermentative is：Jasmine powder and antarctic candidia lipase are added Fermented into solvent orange 2 A, it is 7.6 to control fermentation pH, and fermentation temperature is 60 DEG C, after fermentation, filtered, concentration, overcritical extraction Take and obtain the jasmine extractive from fermentative.
Preferably, the weight ratio of the jasmine powder and antarctic candidia lipase is 17:1, the solvent orange 2 A is anhydrous second Alcohol.
Wherein, the preparation method of the haw thorn extract is：Take 7Kg hawthorn add to 17L volume fraction be 45% Ethanol in, it is well mixed and after soaking 1.5h, high-pressure homogeneous processing 2min is carried out with 350MPa pressure, then decompression filters, Filtrate is obtained, filtrate is evaporated to the haw thorn extract for obtaining general flavone content 83.2%.
Wherein, the extracting method of the kudzu root extract is：Kudzu-vine root powder is subjected to heating and refluxing extraction 2 times, filtering, merged Filtrate, concentration obtain the kudzu root extract, wherein the solvent that uses of each heating and refluxing extraction is 75% for volume parts Ethanol solution.
Wherein, the hawthorn is Shanxi Wild hawthorn.
Wherein, the root of kudzu vine is Jiuhuashan Wild Pueraria.
Embodiment 5
A kind of blood-fat reducing composition, include the raw material of following parts by weight：
40 parts of jasmine extractive from fermentative
10 parts of haw thorn extract
15 parts of kudzu root extract.
Wherein, the preparation method of the jasmine extractive from fermentative is：Jasmine powder and antarctic candidia lipase are added Fermented into solvent orange 2 A, it is 7.2 to control fermentation pH, and fermentation temperature is 50 DEG C, after fermentation, filtered, concentration, overcritical extraction Take and obtain the jasmine extractive from fermentative.
Preferably, the weight ratio of the jasmine powder and antarctic candidia lipase is 22:1, the solvent orange 2 A is anhydrous second Alcohol.
Wherein, the preparation method of the haw thorn extract is：Take 12Kg hawthorn add to 17L volume fraction be 55% Ethanol in, it is well mixed and after soaking 2.5h, high-pressure homogeneous processing 4min is carried out with 250MPa pressure, then decompression filters, Filtrate is obtained, filtrate is evaporated to the haw thorn extract for obtaining general flavone content 81.5%.
Wherein, the extracting method of the kudzu root extract is：Kudzu-vine root powder is subjected to heating and refluxing extraction 2 times, filtering, merged Filtrate, concentration obtain the kudzu root extract, wherein the solvent that uses of each heating and refluxing extraction is 88% for volume parts Ethanol solution.
Wherein, the hawthorn is Shanxi Wild hawthorn.
Wherein, the root of kudzu vine is Jiuhuashan Wild Pueraria.
1-5 of embodiment of the present invention blood-fat reducing composition has obvious drop blood to all kinds of the three high patients through practical proof Effectiveness is pressed, therapeutic effect is high, wherein, with the best results of embodiment 1.Hereinafter, respectively to the blood-fat reducing composition of embodiment 1 Carry out mouse anxious poison experiment, mouse pharmacodynamic experiment and human body pharmacodynamic experiment.
The anxious poison experiment of mouse：4 groups of mouse are taken, every group 10, body weight is in 20 ± 2g, each 5 of male and female, fasting 5 hours, in taking Medicine extractive from fermentative compound preparation for reducing blood fat is by 0.2g/20g, 0.5g/20g, 1.0g/20g respectively to every group of mouse stomach, observation Mouse active situation, observed 4 times in 24 hours, later observation 2 times daily, to 7 days, it is found that mouse administration group and blank group are expert at Dynamic, nervous system reaction and autonomous actions system response no significant difference, LED50It is zero.
Mouse pharmacodynamic experiment：
The preparation of acute high fat of blood animal model：Rat 60 is taken, is randomly divided into 6 groups, every group 10, each 5 of male and female, with Machine is divided into blank control group, model group A, B, C, D, E.Fresh yolk is taken to be configured to 75% emulsion with sterile saline.Model 75% yolk emulsion of doses, 25ml/kg is injected intraperitoneally in group respectively；Blank control group：Isometric physiology salt is injected intraperitoneally Water, after 24 hours, model group mouse orbit is taken a blood sample respectively, take serum after processing centrifugation, survey TC, TG, HDL-C, LDL-C water Flat, model group and blank control group compare, and TC or LDL-C rises, decision model are set up.
After high blood lipid model is set up, the daily gavage physiological saline 10ml/kg of blank control group, model A groups are model comparison Group, daily gavage physiological saline 10ml/kg；The blood-fat reducing composition of embodiment 1 is dissolved in physiological saline blood lipid-lowering composite is made Thing solution, B, C, D group daily gavage blood-fat reducing composition solution 10ml/kg, be converted to the quality of blood-fat reducing composition with Mouse mass ratio, the gavage amount of B, C, D group correspond to 0.7g/kg, 1.4g/kg, 2.1g/kg；E groups are Atorvastatin group, often Its gavage Atorvastatin solution 10ml/kg, dosage 2.1g/kg.Gavage continues 15 days, and every group of mouse orbit is adopted respectively Blood, serum is taken after processing centrifugation, surveys TC, TG, HDL-C, LDL-C level.Obtain following table.
Each experimental group TC/TG data of table 1
TC(mmol/L) TG(mmol/L)
Blank control group 1.43±0.21 1.25±0.16
A groups 4.64±0.18 1.69±0.19
B groups 2.93±0.13 1.57±0.12
C groups 2.61±0.17 1.52±0.18
D groups 2.32±0.12 1.43±0.15
E groups 2.09±0.16 1.28±0.13
As shown in Table 1, mouse TC blank control group, Ah he cut down fourth calcium control group (E groups) and hyperlipidemia model control group (A Group) contrast content it is significant lower, it was demonstrated that modeling success；The content of the wherein middle and high dosage group of blood-fat reducing composition (C, D group) is obvious Less than hyperlipidemia model control group (A groups) (P<0.05), and it is in dosage correlation, there is significant statistical significance.Meanwhile mouse TG blank control group, Ah he cut down fourth calcium control group (E groups) and the significant lower (P of hyperlipidemia model control group (A groups) contrast content< 0.01), it was demonstrated that modeling success；The content of three dosage groups of blood-fat reducing composition (B, C, D group) compares significantly lower than hyperlipidemia model Group (A groups), in dosage correlation, there is significant statistical significance.
Each experimental group LDL-C/HDL-C data of table 2
LDL-C(mmol/L) HDL-C(mmol/L)
Blank control group 1.70±0.32 4.61±0.23
A groups 3.56±0.16 3.52±0.18
B groups 2.91±0.24 4.58±0.14
C groups 2.55±0.19 4.64±0.11
D groups 1..94±0.18 4.72±0.15
E groups 1.82±0.13 4.65±0.13
As shown in Table 2, blank control group significant lower (p ＜ of LDL-C contents compared with hyperlipidemia model control group group (A groups) 0.01), it was demonstrated that modeling success；The LDL-C contents of basic, normal, high three dosage groups (B, C, D group) are less than hyperlipidemia model control group (A Group), content substantially reduces and is in dosage correlation.The HDL-C contents of three dosage groups (B, C, D group) are apparently higher than hyperlipidemia model Control group (A groups), in metering correlation, there is statistical significance.
Human body pharmacodynamic experiment：
Clinical test is carried out with compound preparation made from blood-fat reducing composition produced by the present invention, the compound preparation is by dropping Blood fat composition and excipient are mixed to prepare, and in 100 cases, therapeutic effect is up to 96.00%.Below with the actual case in part Example is described further：
Patient Mr. Wang, male, 56 years old, restaurant boss, there are more than 2 years smoking history, height 1.72m, body weight 85KG, patient's Yin Gao blood Pressure is medical, and inspection result shows CHO (T-CHOL)：8.9mmol/L, TG (triglycerides)：6.83mmol/L diagnosis：Mixing Type hyperlipidemia.Strict smoking cessation is advised, the compound preparation of the present invention is taken, each 3g, checks blood fat 3 times a day, after January and show：CHO (T-CHOL)：7.8mmol/L, TG (triglycerides)：5.60mmol/L, patient react without discomfort, advise the same following the service, balanced meals Food, strengthen motion exercise, positive control body weight, regular follow-up.
Patient it is military certain, female, 50 years old, peasant, height 1.61m, body weight 62KG, because of " it was found that coronary artery atheromatous plaque first quarter moon " just Examine, ferritic is healthy, and lipid examination shows：CHO (T-CHOL)：8.1mmol/L, TG (triglycerides)：6.40mmol/L.Coronary artery is color It is super to show that Atherosclerotic Vessels: Changes Observed during Coronary is formed.Diagnosis：1. combined hyperlipidemia familial；2. Atherosclerotic Vessels: Changes Observed during Coronary is formed.Take this Real compound preparation is invented, each 3g, 3 times a day, blood fat is checked after January, is shown：CHO (T-CHOL)：7.1mmol/L, TG (triglycerides)：5.20mmol/L, patient react without discomfort, advise the same following the service, balanced diet, strengthen motion exercise, monitor body Weight, treatment is checked after 2 months to be shown：CHO (T-CHOL)：6.6mmol/L, TG (triglycerides)：4.60mmol/L regular follow-up.
Above-described embodiment is the preferable implementation of the present invention, and in addition, the present invention can be realized with other manner, Do not depart from and any on the premise of present inventive concept obviously replace within protection scope of the present invention.

Claims (10)

  1. A kind of 1. blood-fat reducing composition, it is characterised in that：Include the raw material of following parts by weight：
    Jasmine extractive from fermentative 10-80 parts
    Haw thorn extract 5-20 parts
    Kudzu root extract 5-20 parts.
  2. A kind of 2. blood-fat reducing composition according to claim 1, it is characterised in that：The blood-fat reducing composition includes as follows The raw material of parts by weight：
    Jasmine extractive from fermentative 20-70 parts
    Haw thorn extract 10-15 parts
    Kudzu root extract 10-15 parts.
  3. A kind of 3. blood-fat reducing composition according to claim 1, it is characterised in that：The blood-fat reducing composition includes as follows The raw material of parts by weight：
    Jasmine extractive from fermentative 30-60 parts
    Haw thorn extract 10-15 parts
    Kudzu root extract 10-15 parts.
  4. A kind of 4. blood-fat reducing composition according to claim 1, it is characterised in that：The blood-fat reducing composition includes as follows The raw material of parts by weight：
    45 parts of jasmine extractive from fermentative
    12.5 parts of haw thorn extract
    12.5 parts of kudzu root extract.
  5. 5. according to a kind of blood-fat reducing composition described in claim 1-4 any one, it is characterised in that：The jasmine fermentation carries The preparation method for taking thing is：Jasmine powder and antarctic candidia lipase are added in solvent orange 2 A and fermented, control fermentation pH For 7-8, fermentation temperature is 40-70 DEG C, and after fermentation, filtered, concentration, supercritical extract obtain the jasmine fermentation extraction Thing.
  6. A kind of 6. blood-fat reducing composition according to claim 5, it is characterised in that：The jasmine powder and antarctic candida The weight ratio of lipase is 15-25:1, the solvent orange 2 A is absolute ethyl alcohol.
  7. 7. according to a kind of blood-fat reducing composition described in claim 1-4 any one, it is characterised in that：The haw thorn extract Preparation method be：5-15Kg hawthorn is taken to add to 15-25L volume fraction in 40%-60% ethanol, to be well mixed And after soaking 1-3h, high-pressure homogeneous processing 1-5min is carried out with 200-400MPa pressure, then decompression filters, and obtains filtrate, will Filtrate is evaporated the haw thorn extract for obtaining general flavone content 80%-85%.
  8. 8. according to a kind of blood-fat reducing composition described in claim 1-4 any one, it is characterised in that：The kudzu root extract Extracting method be：Kudzu-vine root powder is subjected to heating and refluxing extraction 2 times, filtering, merging filtrate, concentration obtain the root of kudzu vine extraction Thing, wherein the ethanol solution that the solvent that each heating and refluxing extraction uses is 70%-90% for volume parts.
  9. A kind of 9. purposes of blood-fat reducing composition according to claim 1-4 any one, it is characterised in that：By the drop Blood fat composition is used for pharmaceuticals field.
  10. A kind of 10. compound preparation for reducing blood fat according to claim 1, it is characterised in that：By claim 1-4 any one A kind of described blood-fat reducing composition and compound preparation made of pharmaceutic adjuvant mixed pressuring plate.
CN201710783652.0A 2017-09-04 2017-09-04 A kind of blood-fat reducing composition and application thereof and compound preparation Pending CN107669760A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710783652.0A CN107669760A (en) 2017-09-04 2017-09-04 A kind of blood-fat reducing composition and application thereof and compound preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710783652.0A CN107669760A (en) 2017-09-04 2017-09-04 A kind of blood-fat reducing composition and application thereof and compound preparation

Publications (1)

Publication Number Publication Date
CN107669760A true CN107669760A (en) 2018-02-09

Family

ID=61136114

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710783652.0A Pending CN107669760A (en) 2017-09-04 2017-09-04 A kind of blood-fat reducing composition and application thereof and compound preparation

Country Status (1)

Country Link
CN (1) CN107669760A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109463492A (en) * 2018-11-22 2019-03-15 河南农业大学 A kind of preparation method and health care product of woody blood-fat reducing composition
CN116832115A (en) * 2023-05-22 2023-10-03 生命之花(北京)健康管理有限公司 Tea pigment composition with blood lipid reducing function, preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1596939A (en) * 2004-07-28 2005-03-23 鞍山制药有限公司 Chinese patent drug for treating heart brain blood vessel disease and its preparation method
CN106890225A (en) * 2017-03-16 2017-06-27 杨本雷 A kind of pharmaceutical composition of reducing blood lipid and preparation method thereof, preparation and application
CN107320545A (en) * 2017-06-26 2017-11-07 郑州海斯威生物技术有限公司 A kind of herb fermenting extract weight-reducing preparation and preparation method thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1596939A (en) * 2004-07-28 2005-03-23 鞍山制药有限公司 Chinese patent drug for treating heart brain blood vessel disease and its preparation method
CN106890225A (en) * 2017-03-16 2017-06-27 杨本雷 A kind of pharmaceutical composition of reducing blood lipid and preparation method thereof, preparation and application
CN107320545A (en) * 2017-06-26 2017-11-07 郑州海斯威生物技术有限公司 A kind of herb fermenting extract weight-reducing preparation and preparation method thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109463492A (en) * 2018-11-22 2019-03-15 河南农业大学 A kind of preparation method and health care product of woody blood-fat reducing composition
CN116832115A (en) * 2023-05-22 2023-10-03 生命之花(北京)健康管理有限公司 Tea pigment composition with blood lipid reducing function, preparation method and application thereof
CN116832115B (en) * 2023-05-22 2024-02-09 生命之花(北京)健康管理有限公司 Tea pigment composition with blood lipid reducing function, preparation method and application thereof

Similar Documents

Publication Publication Date Title
CN102438642A (en) Composition comprising green tea extract
CN108348565A (en) A kind of composition for preventing and treating muscle disease or improving muscle function containing Radix Platycodonis extract
CN101190280B (en) Use of extract of non-fruit part of prune tree
EP1013278B1 (en) The extract of pine needle and the use thereof
WO2015190872A1 (en) Pharmaceutical composition containing spirulina maxima extract as active ingredient for treating and preventing obesity
CN107669760A (en) A kind of blood-fat reducing composition and application thereof and compound preparation
CN107412439A (en) The ginseng composition and preparation method of auxiliary adjustment menopause symptom and anti-cancer and cancer-preventing
WO2018040008A1 (en) Biological traditional chinese medicine for oral administration for treating diabetes mellitus and preparation method therefor
CN105267889A (en) Traditional Chinese medicine preparation for treating hyperlipoidemia
CN101810649A (en) Method for preparing pine needle distilled and concentrated solution
CN1206236C (en) Manyprickle acanthopanax general saponin extractive and its medicinal composition
CN108524811A (en) Reduce uric acid, cholesterol, three high Chinese medicine compositions and its preparation method for the treatment of
CN104547830B (en) A kind of brain boosting oral liquid and preparation method thereof
CN1895540A (en) Medicinal composition for treating cardiovascular disease, its making method and use
CN102204956B (en) Chinese medicinal composition used at stroke recovery period and preparation method thereof
TWI676473B (en) Uses of poria cocos epidermis extract, poricoic acid a, and poricoic acid b in regulating blood glucose level
AU2020101850A4 (en) A pharmaceutical composition for the treatment of diabetes
CN1686242A (en) Composition possessing therapeutic effect for high blood fat and heart brain blood vessel diseases
CN107683922A (en) A kind of Pasania cuspidata Sweet tea and black tea complex tea and its preparation method and application of extract
CN107811907A (en) A kind of body lotion for promoting subcutaneous fat to decompose
CN1857293A (en) Medicine composition containing wild astragaloside and paeoniforin
CN106163535A (en) Comprise the antiobesity agent of Semen Juglandis extract
CN109880725A (en) A kind of cannabidiol health liquor and preparation method thereof relieved fatigue
CN108524870A (en) It is a kind of to have effects that qi-blood tonifying Chinese medicine composition
CN104547909B (en) A kind of Chinese medicine composition of reducing blood lipid and preparation method and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180209